Regeneron Pharmaceuticals Inc.’s first-quarter sales of blockbuster eye drug Eylea came in below Wall Street targets on Thursday as competition heated up, dragging the company’s shares more than 5% lower in early trade.
Tag Archive for: Vabysmo
Just over a year since Genentech and parent Roche gained approval for Vabysmo, an injectable ophthalmic medicine to treat wet age-related macular degeneration and diabetic macular edema, the companies have launched the first DTC ad for the product.
Switzerland’s Roche said first-quarter sales dropped 7% on falling demand for its COVID-19 therapies and tests, less steep than analysts had expected thanks to strong revenue growth from a new eye drug.
Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for castration-resistant prostate cancer, the company revealed Thursday in its 2022 full-year financial report.
Roche warned on Thursday profits will decline in 2023 as falling demand for its COVID-19 therapy and diagnostics kits will knock sales by over $5 billion, the latest sign that the pharmaceutical industry’s years-long pandemic boost is ebbing.
Two Phase III trials of Genentech (Roche)’s Vabysmo hit the primary endpoint in macular edema caused by branch and central retinal vein occlusion (BRVO), showing non-inferiority to Regeneron’s Eylea.
Bayer said on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron (REGN.O), has been shown to work as well when given at a higher dose at a longer interval between injections.
Roche has had a good week, sharing positive two-year data from Genentech’s study on Vabysmo for age-related macular degeneration and eight-year data in its trial for combination therapy for HER2-positive early breast cancer.
